GTOQ yields 7.02% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, GTOQ + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GTOQ + PFE for your $10,000?
IHYF utilizes a factor-based strategy that involves a systematic process that targets securities that that Sub-adviser believes will provide higher returns than other fixed income securities based on quantifiable issuer characteristics or factors. This means that the fund may have higher allocation to value bonds, low volatility bonds and high carry bonds. The funds portfolio managers may change, add and modify these factors as they deem appropriate to minimize certain risks. The fund may also invest in US Treasurys, CDOs, distressed bonds and derivatives at certain limits. Accordingly, the funds allocation limit may be deviated due to market movement. As such, the fund emphasizes the use of derivatives, such as options, futures, forward contracts, swaps, certain mortgage-related securities and asset-backed securities, in an effort to hedge against certain investment risks such as interest rates and foreign currency exposure. IHYF is a truly actively-managed fund.
Full GTOQ Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.